A single-center study suggests that FMT and bezlotoxumab ― two recommended therapies for recurrent C difficile infections ― are not commonly used in Spain, which doesn t appear to align with US practice.
Follow-up that was provided in a general practice led to similar rates of detection of recurrences, and there was no difference in mortality compared to care provided by a surgeon.